Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) announced its financial results for the fourth quarter and full year ended December 31, 2025, alongside a significant corporate update. The company reported a collaboration and license agreement with Chugai Pharmaceutical Co. valued at up to $1.085 billion, aimed at developing an oral therapy utilizing Rani's proprietary RaniPill® platform. This partnership is expected to enhance patient adherence by converting injectable biologics into oral therapies. Additionally, Rani completed a $60.3 million oversubscribed private placement, which included a debt conversion, thereby strengthening its financial position. The company reported cash, cash equivalents, and marketable securities totaling $49.7 million as of December 31, 2025, an increase from $27.6 million in the previous year. Rani's contract revenue for the fourth quarter was $1.5 million, attributed to a License and Collaboration Agreement, reflecting a strategic shift towards monetizing its innovative platform. Rani also highlighted preclinical data demonstrating successful oral delivery of semaglutide and the bioequivalence of its bispecific GLP-1/GLP-2 dual agonist, RT-114, delivered via the RaniPill® capsule. The company initiated a Phase 1 study of RT-114 for obesity treatment in collaboration with ProGen, marking a significant step in its clinical development pipeline. Rani's CEO, Talat Imran, emphasized the company's commitment to advancing its clinical, strategic, and partnership objectives in 2026, positioning Rani well for future growth.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.